Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.

Novartis agreed to pay $310 million upfront, with the possibility for more later, for some research assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker expands the company’s immunology pipeline.

Aldeyra Therapeutics Inc.’s drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.

An advisory committee of the EMA recommended conditionally approving a drug from Akcea Therapeutics and Ionis Pharmaceuticals that aims to treat a rare genetic disease.

The U.S. FDA approved Bausch + Lomb’s Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for treating postoperative inflammation and pain following ocular surgery.

Amgen and AstraZeneca announced that the U.S. FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.

  CAMBRIDGE, England (PRWEB) August 02, 2018 Atlantic Healthcare plc (Atlantic Healthcare), a specialist gastrointestinal (GI) pharmaceutical company, developing treatments for inflammatory bowel disease and other GI diseases, has appointed […]

Pfizer Inc. announced that the company will organize into three businesses: Innovative Medicines, Established Medicines, and Consumer Healthcare.

Optinose announced that the U.S. FDA approved the company’s New Drug Application for XHANCE for treating nasal polyps in patients 18 years of age and older.

Humira

AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.